

## Media Coverage

Client: AusBiotech  
Publication: R&D Focus Drug News  
Date: 25 October 2011  
Page: Online



A WAGGENER EDSTROM PARTNER

### **Baker IDI Heart and Diabetes Institute partnering opportunity, Worldwide.**

Nelms, Fiona  
117 words  
25 October 2011  
**R & D Focus Drug News**  
RDFN  
NA  
ISSN: 1350-1135  
English  
Copyright 2011 Gale Group Inc. All rights reserved.

At **AusBiotech** 2011, 16-19 October 2011, Adelaide, Australia, Guy Krippner, Medical Chemistry Facilitator at the Baker IDI Heart and Diabetes Institute (Australia), informed R&D Focus that the Institute's targeted MRI contrast agent for the detection of vulnerable atherosclerotic plaques is available for partnering and/or licensing, worldwide. The agent is a single-chain antibody specific for activated platelets, and can be coupled to a nanoparticle of choice or the Institute's proprietary gadolinium-loaded polylysine dendrimer. Preclinical development is ongoing in Australia.

contrast agent, vulnerable plaque, Baker IDI Heart and Diabetes Institute, T1E, MRI Agents, Baker IDI Heart and Diabetes Institute, partnering opportunity, Worldwide

### **Dimerix partnering opportunity, Worldwide.**

Williams, James  
137 words  
25 October 2011  
**R & D Focus Drug News**  
RDFN  
NA  
ISSN: 1350-1135  
English  
Copyright 2011 Gale Group Inc. All rights reserved.

At **AusBiotech** 2011, 16-19 October 2011, Adelaide, Australia, James Williams, a Director of Dimerix, informed R&D Focus that the company's G-protein coupled receptor-heteromer identification technology (GPCR-HIT) is available for licensing or partnering. GPCR-HIT is a proprietary cell-based assay that enables the systematic identification of GPCRs that form complexes of different receptors (heteromers) in a ligand responsive manner, and compounds that selectively or allosterically act on them. Identification of heteromers is predictive of new drug combination therapies that act synergistically through GPCR heteromer complexes. In addition, the assay can be used to screen compound libraries for heteromer specific compounds, and for profiling of compounds or marketed drugs for heteromer-mediated side effects.

GPCR-HIT, V7A, All Other Non-therapeutic Products, Dimerix, partnering opportunity, Worldwide

### **Biosceptre preclinical evaluation, Australia (cancer).**

102 words  
26 October 2011  
**R & D Focus Drug News**  
RDFN  
NA  
ISSN: 1350-1135  
English  
Copyright 2011 Gale Group Inc. All rights reserved.

# Buchan

A WAGGENER EDSTROM PARTNER

Biosceptre is developing monoclonal antibodies and domain antibodies (DAbs), the smallest functional binding units of antibodies, targeting a cancer marker identified by the company. The target is present in a wide variety of cancer types. Three lead antibodies (two DAbs and one MAb) have been selected for preclinical evaluation in mouse xenograft studies. R&D Focus was updated on the status of this program at **AusBiotech** 2011, 16-19 October 2011, Adelaide, Australia, by Glenn Pilkington, Laboratory & Projects Manager at Biosceptre.